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In particular, the corticospinal tract, anterior corpus callosum and hippocampal fractional anisotropy encompassing a total of 253 ALS patients and189 controls. . In addition, centre-specific factors such as actual scanner variability, scanning time, noise levels and participants age were identified that could affect the variability of the DTI scans.
Müller and colleagues developed a two-stage procedure to regress most of the centre-specific effects out from the results. In a first step, age, voxel size, echo time, number of gradients and field strength were regressed out of the FA maps of the controls and corrected FA maps for all controls were derived. FA maps of controls were then contrasted between centres and only FA maps of centres with less than 10,000 significant voxels between their controls were merged. In addition, residual centre-specific effects (eg. scan time, noise etc) were defined for controls. Secondly, 3-D linear corrections matrices were calculated and applied to the data sets of each site. The two-step procedure was initially performed for the controls scans only, followed by the ALS patients . The study by Müller and colleagues represents a critically important step in the development of DTIderived biomarkers for ALS across multiple sites. Their findings clearly show that applying a two-step correction procedure to regress and account for centre-specific variability, it is possible to increase the sensitivity and specificity of the FA findings. More importantly, the FA results align with the neuropathological staging of TDP-43, relating the DTI changes with underlying pathological changes.
Clearly, imaging across multiple sites is very challenging as the inherent variability across centres can significantly affect the signal-to-noise ratio of any imaging signature, which compromises their utility as endpoint measure for multi-site intervention studies. Various proposals have been designed to overcome these multi-site imaging variability, ranging from shared protocols to 'travelling heads' (ie. one control which is scanned on all sites and all scanners are calibrated according to the controls' scan). The new approach by Müller and colleagues represents a move from dealing with such issues at data acquisition to the analysis stage. The promising findings suggest that it is possible to pool scans across sites, even if there exist significant differences across protocols, to facilitate multi-site collaboration. Such progress will not only impact on imaging collaborations across sites but also moves forward the tangible possibility that DTI may yet become a reliable trial endpoint measure in future disease modifying treatment trials in ALS. 
